To include your compound in the COVID-19 Resource Center, submit it here.

Tesaro doubles after niraparib shows survival benefit

Tesaro Inc. (NASDAQ:TSRO) soared $40.19 (108%) to $77.40 on Wednesday, adding $1.8 billion in market cap, after it said niraparib ( MK-4827) met the primary endpoint of improving progression-free survival (PFS) in the Phase III NOVA trial. The study evaluated niraparib

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE